🔍 Intelligence Synthesis JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes

AI in Medicine News — 2026-09-28 (Mon)

Daily ReportDaily 03:10 + Evening 18:10 (JST) auto-aggregated

Source links point to the original outlet. The AI Integrated Analysis is auto-generated from the headlines below only and is not intended to add facts beyond them. Not investment advice.

Editions of the day: Daily News (Daily 03:10) / Daily News (Evening 18:10)
Daily Report06:16 JST
Source: Google News RSS / regulators and societies / ClinicalTrials.gov / YouTube  ·  Past 48 hours  ·  16 articles
AI INTEGRATED ANALYSIS2026-09-28 (Mon) — Daily Report · 06:16 JST
Several movements were seen in the diagnostic/imaging field (breast cancer screening, pancreatic cancer risk prediction, pathology/image-based technology).

Latest news on AI and cancer treatment

Overview

Several movements were seen in the diagnostic/imaging field (breast cancer screening, pancreatic cancer risk prediction, pathology/image-based technology). In the field of treatment selection and drug discovery, an AI drug discovery partnership with Roche was reported. Separate regulatory approval/designation information is not included in the heading.

Breast cancer

- Target: Breast cancer recurrence risk assessment. Study shows AI can provide more precise prediction of recurrence risk (MedicalNewsToday, no detailed research stage). - Target: Mammography for breast cancer detection. It was reported that India's PGIMER (Institute of Medical Research and Education) is proceeding with the introduction of AI-assisted mammography equipment (introduction stage, no clinical results listed).

lung cancer

No relevant information (there is a general oncology-related report in the headline stating that AI informs doctors of the uncertainty regarding the success of cancer treatment, but there is no mention specific to lung cancer).

Malignant brain tumor

No applicable information

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

- Target: Pancreatic cancer risk. It was reported that a research team at the Mayo Clinic has developed an AI model that predicts the risk of pancreatic cancer up to three years before the onset of the disease (single-center study, development stage; forward-looking/retrospective and accuracy indicators are not listed in the headline).

Rare cancer

No applicable information

Diagnosis/Pathology/Image

- It was reported that there is a system in which AI notifies doctors when AI is uncertain about the likelihood of success in cancer treatment (Bioengineer.org, target cancer type and verification stage not listed). - The introduction of "Agentic AI" (autonomous AI) into the field of medical oncology and its development from AI joint decision-making support to autonomous tumor board operations was discussed (Oncodaily, concept/perspective article). - A survey on knowledge, attitude, and awareness of AI among medical students was reported (Cureus, an education/awareness survey, not an evaluation of clinical performance).

Treatment selection/drug discovery

- It was reported that Roche Holding has entered into a new AI drug discovery partnership (Yahoo Finance, no details on development stage or target disease). - It was reported that Heidelberg was recruiting for medical AI-related postdocs, engineers, and researchers (information on research infrastructure, not an announcement of results).

Regulations/Approval

No relevant information (There is an editorial titled ``Why excellent medical AI continues to fail in clinical practice,'' but the heading does not include information on approval and designation of individual products by FDA, EMA, and PMDA.)

Clinical trial implementation status

No relevant information (No specific description of the trial name, target cancer type, phase, or registration status from ClinicalTrials.gov can be found in the provided text).

Japanese movements

No applicable information

Remarks from VIPs

No relevant information (the list of important people being tracked is blank, and quotations with titles are not included in the headings).

Note: This report is based solely on the headline text provided and does not refer to the text of the linked article. Numerical values, causal relationships, and clinical significance are not described beyond the scope specified in the heading.

Latest news on AI and rare and incurable diseases

Overview

Only three headlines were collected this time, and there is little concrete content indicating major progress in diagnosis, therapeutic drugs, or systems. There are fragments of stock news on genome-related stocks, a doctoral student's efforts on applying machine learning to gene therapy, and an academic conference presentation on retinal inflammation detection using AI. There are no headlines that directly refer to shortening the diagnosis of designated intractable diseases, approving therapeutic drugs, or reforming the system.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

A stock-related article about TEMPUS AI (NASDAQ: TEM) was found, but the content was chart information for investors, and it was not possible to confirm from the headline what kind of genetic analysis and mutation determination the company had conducted in the rare disease field. Since there is no description of specific analysis methods, judgment accuracy, or target diseases, it is not possible to evaluate the content.

Development of therapeutic drugs

There is a headline that a doctoral student at the University of North Carolina at Chapel Hill in the US is working on gene therapy research using machine learning. The stage is not clear from the headline, and it is not possible to determine whether it is in the preclinical stage or the basic research stage. There is no specific description of target disease names, drug names, or effects.

Nerve/muscular diseases

No applicable information

Immunology/Collagen disease

At Retina Society 2026, it was announced that AI can detect retinal inflammation without using staining. The target disease name, number of cases, and detection accuracy are unclear from the headline, and the information is only at the presentation stage at an academic conference (it is not possible to confirm whether it is a peer-reviewed paper or a case report). A direct relationship with the immunological disease group listed in the heading (Takayasu's arteritis, Behcet's disease, etc., 348 diseases included in the above list) has not been shown.

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

No applicable information

Japanese movements

No applicable information

Remarks from VIPs

No applicable information

💊 Treatment and drug discovery2
⚖️ Regulation and approvals1
🧬 Genomics1
💊 Therapies in development1
🛡️ Immune and connective tissue1
Daily Report18:17 JST
Source: Google News RSS / regulators and societies / ClinicalTrials.gov / YouTube  ·  Past 48 hours  ·  34 articles
AI INTEGRATED ANALYSIS2026-09-28 (Mon) — Daily Report · 18:17 JST
In the diagnostic field, progress has been made in the implementation of image diagnostic AI, with Lunit's AI breast cancer screening being rolled out across the entire Stockholm prefecture in Sweden.

Latest news on AI and cancer treatment

Overview

In the diagnostic field, progress has been made in the implementation of image diagnostic AI, with Lunit's AI breast cancer screening being rolled out across the entire Stockholm prefecture in Sweden. In the drug discovery and clinical trial field, Nutshell Therapeutics' AI-generated compound received FDA IND (investigational new drug) clearance, and the cost-reducing effects of AI-based clinical trial monitoring tools were also reported. There are limited reports regarding formal approval and designation by regulatory authorities (FDA/EMA/PMDA).

Breast cancer

It has been reported that Lunit (Korea)'s AI interpretation solution for breast cancer screening will be supplied to the entire breast cancer screening business in Stockholm County, Sweden. The company is said to have expanded into weekly medical check-up business after accumulating experience in clinical research and actual medical treatment at a hospital in the prefecture for five years. In some news reports, there is a headline that says ``It replaces the interpretation of one radiologist,'' but this is just a media outlet's expression, and specific figures such as accuracy and detection rate are not shown in the headline. Separately, there is a research report in Japanese reporting that ``AI evaluates the risk of late recurrence of breast cancer from pathological images and genetic information,'' but the number of patients targeted, verification method, and stage of evidence (retrospective/prospective, etc.) are unclear from the headline.

lung cancer

We were unable to find any content directly targeting lung cancer among the headings classified in this category. There are reports that Alibaba DAMO has announced an "AI model for cancer and abdominal CT," but details of the targeted organs and cancer types are not listed in the headline. Reports on Xsight Group's AI agent collaboration and DeepTek's cost reduction of tuberculosis (TB) screening AI do not mention lung cancer itself.

Malignant brain tumor

No applicable information

Leukemia/lymphoma

None of the headlines classified in this category (Raspberry AI's application to the apparel industry, Bill Gates' AI safety remarks, Peter Diamandis' moonshot theory, Meta "Muse" AI agent) are directly related to blood cancer diagnosis, stratification, or treatment selection.

Colon cancer/digestive organ

There are reports that an AI that predicts the risk of pancreatic cancer three years in advance has been developed (medicaldialogues.in). However, the size of the target cohort, verification method (preclinical/retrospective/prospective, etc.), and indicators of predictive accuracy are unclear from the headline.

Rare cancer

We were unable to confirm content specific to rare cancers such as adenoid cystic carcinoma. The headline of the related category is that OpenEvidence, which claims to be ``ChatGPT for Doctors,'' has raised $250 million to expand its business into the drug discovery field, but the headline does not mention any specific application to the rare cancer field.

Diagnosis/Pathology/Image

- It has been pointed out (news-medical.net) that biomarkers identified by AI "may appear accurate at first glance, but may fail in the biggest tests". The specific cancer type and verification method are unclear from the headline. - It is reported that the Radiological Society of North America (RSNA)'s AI certification program has been "significantly revamped." - DeepTek introduces global access pricing for 138 countries for AI for tuberculosis screening. - Indian newspaper The Hindu publishes a special feature on the potential of medical AI and patient safety risks.

Treatment selection/drug discovery

- It is reported that a clinical trial monitoring tool using AI has reduced clinical trial costs (stage unknown, the-scientist.com). - Nutshell Therapeutics announced that it has received FDA IND (investigational new drug) clearance for NTS231, a compound that induces NRF2 degradation discovered using AI. This corresponds to the transition stage from preclinical to clinical (assumed Phase I). - Deep Origin announced that it will deploy an ADMET (absorption, distribution, metabolism, excretion, toxicity) prediction AI model to the entire drug discovery program (the stage is presumed to be the entire drug discovery process and the preclinical stage, but it is not specified in the headline). - South Korea's Hits plans to release an AI drug discovery support "AI co-scientist" tool in November, raising 18.3 billion won. - It is reported that a cancer drug maker in which Nvidia invests is planning an initial public offering (IPO). There is no specific information in the heading regarding the efficacy or approval status of the drug. Evaluations and recommendations regarding stocks are outside the scope of this report.

Regulations/Approval

It is reported that the FDA has granted IND (Investigational New Drug, notification before the start of clinical trials) clearance for Nutshell Therapeutics' NRF2 degradation-inducing compound "NTS231." This is a regulatory procedure that allows the start of clinical trials (Phase I) and does not imply approval of efficacy or safety. Others (such as AI infrastructure infrastructure development by a Korean investment company, AI drug discovery formulation design by Okuma Pharmaceutical, and government AI infrastructure business order received by Samsung SDS) are reports on investment and business projects that are different from the approval and designation of drugs and medical devices by the FDA, EMA, and PMDA, and do not fall under this item.

Clinical trial implementation status

The information provided this time does not contain specific information on the individual trial name, target cancer type, phase, or registration status derived from ClinicalTrials.gov, and there is no relevant information.

Japanese movements

Japanese media (BigGo Finance, The Medical AI Times, Japanese reprints of 매일경제, etc.) have introduced overseas developments such as Lunit (South Korea) supplying AI for breast cancer screening in Stockholm Prefecture and Hits (South Korea) raising funds to develop AI drug discovery support tools. We could not confirm any reports regarding the introduction or approval of unique AI by domestic medical institutions or regulatory authorities. Even in a report that states, ``AI assesses the risk of late recurrence of breast cancer from pathological images and genetic information,'' it is not possible to identify the entity conducting the research (domestic or overseas) from the headline.

Remarks from VIPs

- Bill Gates (no title listed, reported by Forbes): He reportedly said that concerns about the safety of AI are "not a hoax," indicating a position contrary to Trump's. The detailed context and target area of the statement (whether it is limited to cancer treatment or not) is unclear from the headline. - There are also reports about Peter Diamandis (moonshot theory) and the new CEO of South Korea's Sangmidang (former Kakao Pay COO, Han Seo-woo), but the headlines do not mention statements directly related to cancer medical AI.

Latest news on AI and rare and incurable diseases

Overview

Only one headline was provided, which was a university announcement regarding emergency endoscopic evaluation support using AI, and no direct movement toward diagnosis, therapeutic drugs, or designated intractable diseases itself could be confirmed. In terms of systems, there are no concrete developments in the headlines regarding medical expense subsidies for designated intractable diseases or research teams. Overall, during this collection period, there is a paucity of AI-related news specializing in rare and incurable diseases.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

No applicable information

Development of therapeutic drugs

No applicable information

Nerve/muscular diseases

No applicable information

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

- Meijo University announced an initiative to use AI to quickly determine the "need for emergency endoscopy" in emergency patients (Infoseek). Expectations were expressed for reducing the burden on doctors on duty and maintaining the local medical system. However, the target disease, number of cases, and verification stage (preclinical/case report/observational study, etc.) are not listed in the heading and are unknown. A direct relationship with designated intractable diseases cannot be confirmed from the headline.

Japanese movements

- The above announcement by Meijo University is the only confirmed domestic movement. This is a report on the use of AI for emergency endoscopy diagnosis, and is introduced as an initiative aimed at improving local medical systems (particularly to address the shortage of doctors on duty).

Remarks from VIPs

No applicable information

← 2026-09-27Index2026-09-29 →
← AI in Medicine News Index